LLY News and Press, Eli Lilly and Company From 01/28/24

2024-01-28 12:00:53 ET More on Amgen, Vertex Pharma, etc. Biotech And Pharma Diversification Pays Off Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar...

2024-01-28 09:30:54 ET Summary Nuveen Growth Opportunities ETF is an actively managed fund with a focus on growth and quality. It is slightly inferior to the S&P 500 Growth Index regarding valuation and cash flow growth, but quality metrics are excellent. Its performance s...

2024-01-27 08:25:00 ET The six most valuable companies in the world by market cap all have one thing in common: each is valued at over $1 trillion. Five of the six are in the technology business, with the exception being Saudi Arabian Oil . With a market cap of roughly $592 bill...

2024-01-27 00:30:00 ET Summary Within the blue chip S&P 100 (the largest stocks in the US), there are currently ten stocks that are up at least 40% over the last two years and 20% over the last three years. On average, these ten stocks have a dividend yield of around 1% and a ...

2024-01-26 14:15:39 ET More on Perspective Therapeutics, Lantheus, etc. Lantheus Stock: Looking To Add After SPLASH's Belly-Flop Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus app...

2024-01-26 14:10:51 ET Summary Low-cost ETFs are advantageous for long-term wealth accumulation due to low expense ratios, diversification, and flexibility. SCHG and SCHD are both some of the best low-cost ETFs in the market today. We compare them side-by-side and offer our pe...

2024-01-26 10:31:26 ET Summary Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for heart failure, and this could become a more signi...

2024-01-26 07:16:34 ET More on Cigna, CVS Health, etc. Humana: The $300 Level Could Get Taken Out In The Near Future Humana Inc. (HUM) Q4 2023 Earnings Call Transcript CVS Health: Back In The Buy Column Humana gets downgrade at Deutsche Bank as stock nears fo...

2024-01-26 06:46:53 ET Barely four years ago, El Lilly (NYSE:LLY) was trading at just around $130. Fast forward, the stock trades at a whopping $627, having recently rubbed a new record price above $645. That represents a price increase of nearly 400%. The return in the past year is als...

2024-01-25 11:28:40 ET More on S&P 500 Index: The Most Important New All-Time High Has Yet To Be Achieved Fed Preview: Expect Interest Rate Cuts In May, June, November And December Attention Turns To Lagarde's Press Conference And U.S. Q4 GDP Tractor Supp...